Therapeutic potential of statins in thyroid proliferative disease

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 5, 2008, Pages 242-243

  Bifulco, Maurizio ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ONYX 015;

APOPTOSIS; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; DRUG INHIBITION; ENZYME ACTIVITY; GENE THERAPY; GOITER; HUMAN; ISCHEMIC HEART DISEASE; MUSCLE TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; THYROID DISEASE;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; THYROID NEOPLASMS;

EID: 42449154250     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0782     Document Type: Short Survey

References (10)

1. Bifulco M et al. (1999) Inhibition of farnesylation blocks growth but not differentiation in FRTL-5 thyroid cells. Biochimie 81: 287-290
2. Vitale M et al. (1999) Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent, CrmA-sensitive, and caspase-3-like protease-dependant mechanism. Endocrinology 140:698-704
3. Laezza C et al. (2006) HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway. J Mol Med 84:967-973
4. Cappelli C et al. (2008) Reduced thyroid volume and nodularity in dyslipidaemic patients on statin treatment. Clin Endocrinol (Oxf) 68: 16-21
5. Wang CY et al. (2003) Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88: 3021-3026
6. Zhong WB et al. (2005) Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer 12: 615-629
7. Laezza C et al. (1998) v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. Proc Natl Acad Sci USA 95: 13646-13651
8. Bifulco M (2005) Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis. Life Sci 77: 1740-1749
9. Libertini S et al. (2007) Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology 148: 5186-5194
10. Friedman GD et al. (2007) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf [doi:10.1002/pds.1507]